AbbVie Announces Positive Topline Results From Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg,…

AbbVie seeks Rinvoq alopecia approval after second Phase III success

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main competitor, Olumiant.The post AbbVie seeks Rinvoq alopecia approval after second Phase III success appeared first on Clinical Trials Arena.

AbbVie’s Rinvoq clears second Phase 3 trial in hair loss disease

AbbVie’s Rinvoq met the primary endpoint in another Phase 3 study for severe alopecia areata, lining the company up for a potential approval to treat the autoimmune hair loss disease. Of the patients assigned to ...